GlaxoSmithKline UK

Stockley Park West, Uxbridge, Middlesex, UB11 1BT
Telephone: +44 (0)800 221 441
Fax: +44 (0)208 990 4328
Medical Information e-mail: customercontactuk@gsk.com


Patient Information Leaflet last updated on the eMC: 01/06/2010
PIL Avandamet Film-Coated Tablets

Avandamet Film-Coated Tablets

On 23 September 2010, the European Medicines Agency recommended the suspension of the marketing authorisations for rosiglitazone-containing anti-diabetes medicines.

Advice for healthcare professionals and patients:

  • Prescribers should put in place a system to ensure that all patients are reviewed and changed to another suitable treatment in line with NICE recommendations.
  • While this change could happen at the next routine appointment, prescribers may wish to see patients sooner rather than later in order to reduce patient anxiety.
  • Patients who are concerned should not stop their treatment but should contact the healthcare professional supervising their diabetic treatment.

Further information can be found on the MHRA website:

http://www.mhra.gov.uk/Safetyinformation/Safetywarningsalertsandrecalls/Safetywarningsandmessagesformedicines/
CON094121


The Patient Information Leaflet (PIL) is the leaflet included in the pack with a medicine. It is written for patients and gives information about taking or using a medicine. This PIL is in PDF format.

View Patient Information Leaflet (2.45MB)

Are you having problems printing this pdf? Please click here for help.

Can't read the PDF? Visit adobe.com and download the Adobe Acrobat Reader.


More information about this product

Link to this document from your website: http://www.medicines.org.uk/emc/medicine/13397/PIL/


Active Ingredients/Generics

 
   rosiglitazone
   metformin hydrochloride